SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

Article Details

Citation

Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG, McKechney MW, Pillar JD, Watson JW

SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

J Med Chem. 2007 Jan 25;50(2):344-9.

PubMed ID
17228876 [ View in PubMed
]
Abstract

The potency and physical properties of a previously reported 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the lactam moiety into a triazolo ring. The resulting 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine series provided nonionizable analogs with melting point properties suitable for micronization. Substitution at the 3-position of the 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine tricycle led to a 2-thienyl analog, 19 (tofimilast), a potent PDE4 inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concentrations up to 152 ng/mL.

DrugBank Data that Cites this Article

Binding Properties
DrugTargetPropertyMeasurementpHTemperature (°C)
(R)-RolipramcAMP-specific 3',5'-cyclic phosphodiesterase 4BIC 50 (nM)231N/AN/ADetails
(R)-RolipramcAMP-specific 3',5'-cyclic phosphodiesterase 4DIC 50 (nM)622N/AN/ADetails
PiclamilastcAMP-specific 3',5'-cyclic phosphodiesterase 4AIC 50 (nM)4N/AN/ADetails
PiclamilastcAMP-specific 3',5'-cyclic phosphodiesterase 4BIC 50 (nM)3N/AN/ADetails
PiclamilastcAMP-specific 3',5'-cyclic phosphodiesterase 4CIC 50 (nM)14N/AN/ADetails
PiclamilastcAMP-specific 3',5'-cyclic phosphodiesterase 4DIC 50 (nM)2N/AN/ADetails